Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate Capsule, Extended Release
FDA Label NDC 0228-3060

44 label sections · Submitted to the FDA by Actavis Pharma, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Actavis Pharma, Inc. for the product Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, Amphetamine Sulfate (NDC 0228-3060). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: abuse, misuse, and addiction, 1.1 attention deficit hyperactivity disorder, 2.1 pretreatment screening, 2.2 general administration information, 2.3 recommended dosage in pediatric patients 6 to 12 years, 2.4 recommended dosage in pediatric patients 13 to 17 years, 2.5 recommended dosage in adults, 2.6 dosage in patients with renal impairment, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.